India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there
|出版日期||內容資訊||英文 22 pages
|印度製藥業潛力企業：傳統開發於醫藥產業被取代 India Rising Stars Outlook 2015: Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there|
|出版日期: 2015年01月21日||內容資訊: 英文 22 pages||
傳統醫藥產業技術革新與創藥 (藥物開發) 在印度製藥企業僅剩零星。新世代企業誕生、從對製藥業沒有經驗的創業投資 (VC) 獲得資金並且開始挑戰創藥。
Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. However, there have a been a new generation of entrepreneurs who have who ventured into the drug discovery path backed by VC funding and no pharma heritage ! In this Outlook we highlight the names of some select innovation/drug discovery companies who have successfully raised funds to sustain the research, out-licensed some of their assets or are likely to do so in the next 2-3 years thereby rewarding their investors. . In this Outlook we have initiated coverage on Connexios, Bugworks, Cellworks, Tergene and hope that soon we will be able to expand the universe further.
Connexious - Connexios has had a bumpy ride like most Rising stars/drug discovery.
Cellworks - Cellworks (CW) has evolved from a service based company to a drug discovery/development company on the strength of its proprietary Virtual Prototyping platform that allows simulation of cell types//disease in silico.
Bugworks - Bugworks is a validation of Cellworks simulation in silico Technology Platform where its Bugworks Microbial Platform (BMP) combines functional proteomics with sophisticated semiconductor designe engineering to model and manipulate various bacterial systems.
Tergene - Tergene's first product in development is a vaccine for pneumonia caused by, Streptococcus pneumonia (pneumococcous). The available vaccine The Pneumococcal Polysaccharide Vaccines (PPV).